RNAZ

Quote

Short

News

Articles

Message Board

TransCode Therapeutics Inc. (NASDAQ : RNAZ ) News

TransCode Therapeutics Inc. (NASDAQ: RNAZ) News Releases

RNAZ News Releases

June 08, 2026 09:45:00 am

InvestorWire

InvestorNewsBreaks - TransCode Therapeutics, Inc. (NASDAQ: RNAZ) to Host First R&D Webcast Highlighting Phase 2a Oncology Program

June 08, 2026 08:04:00 am

PR Newswire

TransCode Therapeutics to Host R&D Webcast on June 18, 2026

June 03, 2026 10:10:36 am

BioMedWire

BioMedNewsBreaks - TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Reports Positive Phase 1a Results for TTX-MC138 and Advances Program Toward Phase 2a

June 03, 2026 10:00:42 am

QM US Market Movers News

US Companies Moving the Markets, Morning edition
Wed, Jun 03, 2026 as of 10.00 am ET

June 03, 2026 08:04:00 am

PR Newswire

TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer

May 27, 2026 09:15:19 am

BioMedWire

BioMedNewsBreaks - TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Initiates Phase 2a Trial of TTX-MC138 in Colorectal Cancer Patients with Minimal Residual Disease

May 27, 2026 08:04:00 am

PR Newswire

TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer

April 27, 2026 09:25:00 am

InvestorWire

InvestorNewsBreaks - TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints Scientific Advisory Board Chair, Signs Research Agreement With Michigan State University

April 27, 2026 08:02:00 am

PR Newswire

TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University

April 07, 2026 10:04:41 am

MissionIR

MissionIRNewsBreaks - TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Secures Up to $20 Million Financing Agreement

	Next 10

Subscribe to Our Newsletter

Download The Market Wire News App

Link Market Wire News to Your X Account